Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

June 25, 2019

BMS plans to sell Celgene’s psoriasis drug Otezla

Bristol-Myers Squibb (BMS) is planning to divest Celgene’s psoriasis drug Otezla (apremilast), in a bid to expedite the process of merger with Celgene.

BMS plans to sell Celgene’s psoriasis drug Otezla